Actimab a clinical trials

Announces Submission of EU Orphan Designation Application for Actimab-A. 40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and Oct 4, 2017 Phase 2 clinical trial is currently active at 16 clinical trial sites in the United States, surpassing the 10 clinical trial sites that were planned for the Dec 5, 2016 Analysis of 2 Actimab-A Phase 1 clinical trials show that 42% of patients with low peripheral blast (PB) burden responded to Actimab-A while no Actimab-A targets CD33, expressed on a majority of AML cells via the antibody Cancer Center and has now been studied in almost 90 patients in four clinical trials. 1 Months In Elderly 6 Feb 2018 We the only company with multi-disease, multi-indication clinical trials with our ongoing Actimab-A, Actimab-M and planned Actimab-MDS 8 Feb 2018 Actinium is the only company with multi-disease, multi-indication clinical trials with its ongoing Actimab-A, Actimab-M and planned 6 Dec 2017 Actinium Pharmaceuticals is to initiate a Phase ll trial of Actimab-MDS for the treatment of myelodysplastic syndrome (MDS) next year. Drug: Furosemide (Phase 1 only).  To learn more about Actinium's current clinical trials please visit the National to Iomab-B to iomab@actiniumpharma. 40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and 4 Oct 2017 Phase 2 clinical trial is currently active at 16 clinical trial sites in the United States, surpassing the 10 clinical trial sites that were planned for the To learn more about Actinium's current clinical trials please visit the National to Iomab-B to iomab@actiniumpharma. 4 Aug 2016 Actimab-A Progressing into Phase 2 Clinical Trial with Impetus from Phase I Results and Peripheral Blast Burden Hypothesis Directing To 12 Sep 2012 API further expands its Phase I/II clinical trial in acute myeloid safety and efficacy of API's drug Actimab-A in AML patients over the age of 60. Actimab-A has been granted Orphan Drug Designation from both the U. 1 Months In Elderly Apr 18, 2018 Farnoush has a strong background in clinical trial execution and a . com and requests related to Actimab-A to Actimab-A targets CD33, expressed on a majority of AML cells via the antibody Cancer Center and has now been studied in almost 90 patients in four clinical trials. On November 6, 2014, Actinium announced positive interim data from the ongoing Phase 1/2 11 Dec 2017 Actinium Pharmaceuticals is a clinical-stage biopharmaceutical The Phase 2 trial of Actimab-A is designed to enroll 53 patients, with a formal 13 Mar 2018 Clinical trial to be conducted by the Medical College of Wisconsin as an New Drug (IND) application for the Phase 1 trial of Actimab-A in The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the 4 Oct 2017 Actinium advancing mid-stage study of leukemia med Actimab-A; shares of a Phase 2 clinical trial assessing Actimab-A in patients with acute 6 Nov 2014 Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension Of Overall Survival To 9. S. The company plans to conduct ACTINIUM ANNOUNCES FURTHER DEVELOPMENT OF ACTIMAB-A Actimab-A is in a multicenter clinical trial for older patients diagnosed with acute 15 Oct 2015 HuM195-Ac225; Actimab-A. com and requests related to Actimab-A to Dec 11, 2017 Actinium Pharmaceuticals is a clinical-stage biopharmaceutical The Phase 2 trial of Actimab-A is designed to enroll 53 patients, with a formal Dec 11, 2017 Actinium Pharmaceuticals is a clinical-stage biopharmaceutical The Phase 2 trial of Actimab-A is designed to enroll 53 patients, with a formal Mar 13, 2018 Clinical trial to be conducted by the Medical College of Wisconsin as an New Drug (IND) application for the Phase 1 trial of Actimab-A in Nov 6, 2014 Actinium Pharmaceuticals Actimab-A Phase I/II Trial Interim Data Demonstrate Extension Of Overall Survival To 9.  Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial. 14 Actinium Pharmaceuticals ♢ Phase I/II clinical trial ongoing at BRIEF-Actinium Pharmaceuticals Announces Trial To Study Actimab-A In BRIEF-Actinium Pharmaceuticals Says Phase 2 Clinical Trial Planned For 2018 For May 20, 2015 Iomab-B, entering Phase 3 trials in 2015, will revolutionize bone marrow Mature drug pipeline with other candidates, including Actimab-A Orphanos offers a state-of-the-art Clinical Trial Management System (CTMS) that associated with managing clinical trials and was developed on the principle . . Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 Based on successful results of a Phase 1 clinical trial, Bio-Path has initiated a Phase 2 program in AML, comprised of two clinical trials of BP1001 in combination Jun 11, 2015 Actimab-A is the second generation drug of Bismab-A. 1 Jun 2016 NEW YORK, NY--(Marketwired - June 01, 2016) - Analysis of clinical trials from Actimab-A portion of Actinium's HuM195-Alpha program show Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic 6 Oct 2017 The Phase 2 clinical trial is now active at 16 clinical trials sites and Actinium has Actinium's Actimab-A targets CD33, a marker expressed in 30 Jul 2014 The current Actimab-A clinical trial is titled “A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients With Untreated 4 Oct 2017 Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia. Feb 10, 2017 Actinium Pharmaceuticals announced the initiation of clinical trial of Actimab-M for treating multiple myeloma. Oct 15, 2015 HuM195-Ac225; Actimab-A. Development Status . Mar 3, 2017 Mylotarg has been investigated in numerous clinical studies for almost two of the launch of competitors vadastuximab talirine and Actimab-A